Abstract
Adeno-associated virus (AAV) vectors have been shown to mediate persistent transduction in animal models of gene therapy. However, clinical trials with AAV vectors have shown that an immune response to AAV capsid protein can result in clearance of transduced cells. One source of capsid antigen is from the delivered vector virions, but expression of cap DNA impurities in AAV vector preparations might provide an alternative and persistent source of capsid antigen. Here we show that DNA without any AAV sequences can be packaged in AAV virions, and that both cap and rep DNA are packaged into AAV vectors produced by standard methods. Using a sensitive complementation assay, we also observed significant expression of capsid in cultured cells transduced with AAV vectors. In an attempt to solve this problem, we inserted a large intron into the cap gene to generate a capsid expression cassette (captron) that is too large for packaging into AAV virions. Both complementation assays and quantitative reverse-transcription PCR analysis showed that cultured cells infected with AAV vectors made with the captron plasmid expressed no detectable capsid. Elimination of transfer of capsid-expressing DNA may reduce immune responses to AAV vector-transduced cells and promote long-term expression of therapeutic proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56–63.
Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH . Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of β-glucuronidase-deficient mice. J Virol 2003; 77: 7034–7040.
Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D et al. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 2003; 7: 774–781.
Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinohe A, Kojima K et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 2004; 11: 1081–1086.
Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.
Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114: 2077–2086.
Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS et al. Sustained AAV-mediated dystrophin expression in a canine model of duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160–1166.
Halbert CL, Madtes DK, Vaughan AE, Wang Z, Storb R, Tapscott SJ et al. Expression of human α1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Mol Ther 2010; 18: 1165–1172.
Allen JM, Debelak DJ, Reynolds TC, Miller AD . Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71: 6816–6822.
Cao L, Liu Y, During MJ, Xiao W . High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 2000; 74: 11456–11463.
Nony P, Chadeuf G, Tessier J, Moullier P, Salvetti A . Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J Virol 2003; 77: 776–781.
Chadeuf G, Ciron C, Moullier P, Salvetti A . Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther 2005; 12: 744–753.
Hauck B, Murphy SL, Smith PH, Qu G, Liu X, Zelenaia O et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 2009; 17: 144–152.
Halbert CL, Allen JM, Miller AD . Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75: 6615–6624.
Halbert CL, Lam SL, Miller AD . High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. Hum Gene Ther 2007; 18: 344–354.
Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671–678.
Stieger K, Schroeder J, Provost N, Mendes-Madeira A, Belbellaa B, Le Meur G et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther 2009; 17: 516–523.
Allen JM, Halbert CL, Miller AD . Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. Mol Ther 2000; 1: 88–95.
Chadeuf G, Favre D, Tessier J, Provost N, Nony P, Kleinschmidt J et al. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med 2000; 2: 260–268.
Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR . Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther 2000; 2: 394–403.
Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 2010; 17: 503–510.
Duan D, Yue Y, Engelhardt JF . Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001; 4: 383–391.
Halbert CL, Allen JM, Miller AD . Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002; 20: 697–701.
Lai Y, Yue Y, Duan D . Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome ⩾8.2 kb. Mol Ther 2010; 18: 75–79.
Wu Z, Yang H, Colosi P . Effect of genome size on AAV vector packaging. Mol Ther 2010; 18: 80–86.
Dong B, Nakai H, Xiao W . Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010; 18: 87–92.
Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828–834.
Boissy R, Astell CR . An Escherichia coli recBCsbcBrecF host permits the deletion-resistant propagation of plasmid clones containing the 5′-terminal palindrome of minute virus of mice. Gene 1985; 35: 179–185.
Halbert CL, Miller AD . AAV-mediated gene transfer to mouse lungs. Methods Mol Biol 2004; 246: 201–212.
Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD . Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71: 5932–5941.
Acknowledgements
We thank Katherine High for providing the ACMVcFIX AAV vector that expresses canine FIX. This work was supported by grants P30 DK47754, UL1 DE19582 and T32 CA09229 from the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Halbert, C., Metzger, M., Lam, SL. et al. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther 18, 411–417 (2011). https://doi.org/10.1038/gt.2010.167
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2010.167
Keywords
This article is cited by
-
Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing
Molecular Biotechnology (2023)
-
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Nature Communications (2017)
-
Adeno-associated-virus-mediated transduction of the mammary gland enables sustained production of recombinant proteins in milk
Scientific Reports (2015)
-
Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model
Gene Therapy (2014)
-
Gene therapies advance, but some see manufacturing challenges
Nature Medicine (2012)